Kinloch Capital’s Amedisys AMED Stock Holding History

Kinloch Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-241	Closed	-$71K	–	69
2020 Q4	$71K	Buy	+241	New	+$61.8K	0.06%	82

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Kinloch Capital's AMED Position: Q1 2021 in Review

Kinloch Capital sold out of Amedisys (AMED) in Q1 2021, closing a stake of 241 shares — an estimated $71K sold.

Kinloch Capital first reported a position in AMED in Q4 2020 and held it in 1 quarter. The position peaked at $71K in Q4 2020. 388 funds tracked by Wall St. Rank hold AMED as of Q1 2021.

Kinloch Capital reported no remaining Amedisys position as of Q1 2021 after selling out during the quarter.
Kinloch Capital sold 241 Amedisys shares in Q1 2021, an estimated $71K.
Kinloch Capital first reported a position in Amedisys in Q4 2020 and held it in 1 quarter.
Kinloch Capital's Amedisys position peaked at $71K in Q4 2020.
388 funds tracked by Wall St. Rank held Amedisys as of Q1 2021.

Based on Kinloch Capital's 13F filing for Q1 2021, filed 11 May 2021.